Scholarlink

<p>This study focuses on the synthesis of poly(2-vinylpyridine)-stabilized silver nanoparticles (P2VP-AgNPs) to be employed as a nanocarrier for ceftriaxone (CEF) in order to enhance its therapeutic efficacy. P2VP-AgNPs were synthesized via the chemical reduction method using P2VP as a stabilizer, silver nitrate as a silver source, and sodium borohydride as a reducing agent. Characterization of P2VP-AgNPs before and after the loading of CEF was performed using advanced analytical techniques. The CEF loading capacity was evaluated via UV-Vis spectrophotometry, and antimicrobial efficacy was assessed against six bacterial strains using the agar-well diffusion method. The inhibition efficacy of P2VP-AgNPs/CEF has doubled compared to direct application of CEF against six different bacterial strains, including gram-negative as well as gram-positive bacterial strains, which highlights the synergistic impact of this nanocarrier system. The synthesized P2VP-AgNPs exhibited a stable average size of 60.0 ± 2&#xa0;nm and a zeta potential of + 40.0 ± 0.3 mV, which increased to 72.0 ± 2&#xa0;nm and + 45.0 ± 0.3 mV, respectively, upon CEF loading. Over 87% of CEF was successfully loaded and released in a sustained manner, reaching 86% within 100&#xa0;h. FTIR and PXRD analyses confirmed strong drug–nanoparticle interactions and reduced crystallinity, respectively. Antibacterial tests showed a &gt; 2.5-fold increase in efficacy for P2VP-AgNPs/CEF compared to CEF alone, highlighting the potential of this nanocarrier for enhanced antibiotic delivery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ceftriaxone Delivery Via Poly(2-vinylpyridine)-Integrated Plasmonic Nanoparticles for Enhancement in its Therapeutic Efficacy

  • 期刊论文

  • 发表日期：

    2025年10月16日

查看全文
  • Syed Wali Shah,
  • Daim Asif Raja,
  • Sikandar Khan Sherwani,
  • Sajid Jahangir,
  • Muhammad Imran Malik

摘要

This study focuses on the synthesis of poly(2-vinylpyridine)-stabilized silver nanoparticles (P2VP-AgNPs) to be employed as a nanocarrier for ceftriaxone (CEF) in order to enhance its therapeutic efficacy. P2VP-AgNPs were synthesized via the chemical reduction method using P2VP as a stabilizer, silver nitrate as a silver source, and sodium borohydride as a reducing agent. Characterization of P2VP-AgNPs before and after the loading of CEF was performed using advanced analytical techniques. The CEF loading capacity was evaluated via UV-Vis spectrophotometry, and antimicrobial efficacy was assessed against six bacterial strains using the agar-well diffusion method. The inhibition efficacy of P2VP-AgNPs/CEF has doubled compared to direct application of CEF against six different bacterial strains, including gram-negative as well as gram-positive bacterial strains, which highlights the synergistic impact of this nanocarrier system. The synthesized P2VP-AgNPs exhibited a stable average size of 60.0 ± 2 nm and a zeta potential of + 40.0 ± 0.3 mV, which increased to 72.0 ± 2 nm and + 45.0 ± 0.3 mV, respectively, upon CEF loading. Over 87% of CEF was successfully loaded and released in a sustained manner, reaching 86% within 100 h. FTIR and PXRD analyses confirmed strong drug–nanoparticle interactions and reduced crystallinity, respectively. Antibacterial tests showed a > 2.5-fold increase in efficacy for P2VP-AgNPs/CEF compared to CEF alone, highlighting the potential of this nanocarrier for enhanced antibiotic delivery.